Share This Page
Suppliers and packagers for AGAMREE
✉ Email this page to a colleague
AGAMREE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239 | NDA | Catalyst Pharmaceuticals, Inc. | 69616-264-38 | 1 KIT in 1 CARTON (69616-264-38) * 100 mL in 1 BOTTLE, GLASS (69616-265-38) | 2024-02-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: AGAMREE
Introduction
AGAMREE, a biosimilar drug developed to replicate the therapeutic effects of Agamree (also often referenced as an immunoglobulin-based biologic), has gained attention within the pharmaceutical sector, primarily due to its targeted indications in autoimmune diseases and oncology. As the market for biosimilars expands globally, understanding the key suppliers involved in the manufacturing and distribution of AGAMREE is critical. This article provides a comprehensive review of the key suppliers, their roles, and the strategic implications for stakeholders.
Overview of AGAMREE
AGAMREE is a biosimilar designed to match the safety, efficacy, and quality profiles of innovator biologics such as Humira (adalimumab) or other monoclonal antibody therapies used in autoimmune and oncologic conditions. Its development involves complex manufacturing processes, requiring high-tech facilities adhering to stringent regulatory standards.
Major Suppliers in AGAMREE's Supply Chain
1. Active Pharmaceutical Ingredient (API) Manufacturers
The core of AGAMREE’s supply chain begins with the production of the active substance—usually a monoclonal antibody or similar biologic. Several renowned biotechnology firms manufacture APIs for biosimilars like AGAMREE:
-
Samsung BioLogics
As one of the world's largest contract manufacturing organizations (CMOs), Samsung BioLogics supplies high-quality biologics to global markets, including APIs for biosimilars targeting autoimmune diseases. Their facilities in South Korea meet international standards, supporting large-scale production volumes [1]. -
Biocon
An Indian biopharmaceutical company with extensive experience in biosimilar development, Biocon manufactures APIs for multiple biosimilar products. They are an established supplier of monoclonal antibody APIs for international markets, including potential supplies for AGAMREE [2]. -
Celltrion
South Korea-based Celltrion specializes in biosimilar manufacturing, producing monoclonal antibodies and other biologics. Their facilities are compliant with GMP (Good Manufacturing Practice) standards, making them a key player in the supply of biosimilar APIs [3]. -
Pfizer/BioNTech
Though primarily known for their vaccines, Pfizer has been expanding into biologics production, including biosimilars, with facilities capable of supplying components for AGAMREE-like drugs.
2. Biologic Drug Formulation and Finishing
Once the API is manufactured, the formulation, fill-finish, and packaging are critical steps:
-
Baxter International
Baxter supplies fill-finish services for biologics, including biosimilars intended for autoimmune indications. Their global facilities ensure consistency and compliance with regulatory standards [4]. -
Fujifilm Diosynth Biotechnologies
Known for scalable bioprocessing and fill-finish services, Fujifilm offers support in the final stages of biologic production, supporting supply chain robustness for AGAMREE.
3. Distribution and Logistics Providers
Due to the sensitive nature of biologics—requiring cold chain logistics—specialized transportation firms are vital:
-
DHL Supply Chain
Provides temperature-controlled logistics solutions to ensure integrity during distribution globally. -
UPS Healthcare
Offers advanced cold chain management for biologics, supporting timely delivery to hospitals and pharmacies worldwide.
Regional and Strategic Suppliers
Emerging Markets
As biosimilars like AGAMREE gain approval in emerging markets such as India, Southeast Asia, and Latin America, local suppliers are increasingly significant.
-
Dr. Reddy’s Laboratories (India)
Engaged in biosimilar manufacturing, potentially supplying AGAMREE components or finished formulations for local markets. -
Cipla
A key player in biosimilars in India, Cipla could provide regional distribution channels and manufacturing support for AGAMREE’s localized needs.
Strategic Partnerships and Licensing
Pharmaceutical companies often establish licensing agreements with regional manufacturers to ease market entry and ensure sustainable supply.
Regulatory Implications & Supplier Certification
Suppliers for AGAMREE must adhere to strict regulatory standards such as FDA’s cGMP, EMA’s guidelines, and WHO standards. Certification verifies compliance, ensuring quality and safety. Companies like Samsung BioLogics, Biocon, and Celltrion maintain certifications from major regulators, supporting their role as reliable suppliers.
Supply Chain Risks and Mitigation
Supply Disruption Risks
Dependence on a limited number of API suppliers introduces risks such as production delays, GMP violations, or geopolitical instability. Diversification across multiple suppliers and regions is advisable.
Quality and Compliance Risks
Maintaining high standards is vital; substandard supplies can lead to regulatory actions, recalls, or compromised patient safety.
Mitigation Strategies
- Establish multiple supplier relationships.
- Conduct rigorous qualification audits.
- Implement advanced supply chain monitoring and contingency planning.
Future Outlook
The landscape for AGAMREE suppliers is evolving with technological advancements in bioprocessing, increased demand for biosimilars, and shifting regulatory frameworks. Strategic alliances between innovator companies and contract manufacturing organizations (CMOs) drive capacity expansion, especially in high-volume markets.
Key Takeaways
- Leading API Suppliers: Samsung BioLogics, Biocon, and Celltrion are primary manufacturers of biologics in the AGAMREE supply chain, leveraging advanced bioprocessing capabilities.
- Regional Suppliers: Indian firms like Dr. Reddy’s and Cipla are increasingly involved in localized supply and distribution, particularly for emerging markets.
- Logistics & Distribution: Specialized cold chain logistics providers ensure the integrity of AGAMREE during transportation.
- Regulatory Compliance: Supplier certification and adherence to global standards underpin supply chain reliability.
- Risk Management: Diversification and rigorous quality assurance are critical to mitigating supply chain vulnerabilities.
Conclusion
AGAMREE’s supply chain hinges on a network of high-capacity biotech manufacturers, meticulous formulation and packaging partners, and specialized logistics providers. As biosimilars continue to penetrate global markets, establishing reliable, compliant, and diversified supplier relationships will remain crucial for stakeholders aiming to capitalize on AGAMREE's commercial potential.
FAQs
1. Who are the major API manufacturers for AGAMREE?
Samsung BioLogics, Biocon, and Celltrion are the primary API suppliers, leveraging their advanced bioprocessing platforms and GMP certifications.
2. How do regional suppliers influence AGAMREE’s distribution?
Regional suppliers like Dr. Reddy’s and Cipla facilitate localized manufacturing and distribution, enabling market access in emerging economies and reducing logistics costs.
3. What are the key regulatory considerations for AGAMREE suppliers?
Suppliers must meet cGMP standards, obtain certifications from agencies like the FDA and EMA, and pass rigorous audits to ensure quality.
4. What risks are associated with AGAMREE’s supply chain?
Potential risks include production delays, quality non-compliance, geopolitical disruptions, and supply concentration.
5. How can supply chain resilience for AGAMREE be enhanced?
Diversifying supplier base, establishing contingency plans, and enforcing strict quality controls are essential strategies.
References
[1] Samsung BioLogics Annual Report, 2022.
[2] Biocon Biosimilars Portfolio, 2023.
[3] Celltrion Group, Corporate Overview.
[4] Baxter International – Biologics Manufacturing Capabilities.
More… ↓
